BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...undisclosed company. The cancer and rare disease company has launched a search for his successor. Zelluna Immunotherapy A/S...
...is developing TCR-based autologous T and allogeneic NK cell therapies to treat solid tumors (see "Zelluna’s...
...Afa Science’s board and is an advising partner at Advantary, which outsources C-suite services. BioCentury Staff Xencor Institut Gustave-Roussy Zelluna Immunotherapy A/S E-Scape...
BioCentury | Nov 19, 2019
Company News

Nov. 19 Company Quick Takes: Medicines Co. gains on buyout rumor; plus Samsung's biosimilar under review and Zelluna-Glycostem

...commercialize the anti-VEGF antibody in the U.S. Zelluna, Glycostem to develop allogeneic TCR-NK cell therapies Zelluna Immunotherapy A/S...
...Therapeutics B.V.'s umbilical cord-derived NK cells to develop allogeneic TCR-expressing NK cells for solid tumors. Zelluna...
...Vascular endothelial growth factor BioCentury Staff Samsung Bioepis Co. Ltd. Biogen Inc. Merck & Co. Inc. Samsung BioLogics Co. Ltd. Zelluna Immunotherapy A/S The...
BioCentury | Mar 22, 2019
Product Development

Regulating regeneration in Europe

...differences between regulatory pathways in Europe, the U.S. and Japan, said Miguel Forte, CEO of Zelluna Immunotherapy A/S...
...on things like GMOs and how they are regulated is a delaying obstacle." Miguel Forte, Zelluna...
...Administration (FDA), Silver Spring, Md. Zelluna Immunotherapy A/S, Oslo, Norway Lauren Martz, Associate Editor Caladrius Biosciences Inc. Celixir plc ReNeuron Group plc Zelluna Immunotherapy A/S ATMP regenerative...
BioCentury | Jan 17, 2019
Emerging Company Profile

Zelluna’s solid TCR plans

...attack on solid tumors than other TCR-based cell therapies in development. CEO Miguel Forte said Zelluna’s...
...whereas some cancers but few normal cells express HLA class II. Forte said this means Zelluna’s...
...can target a wider range of tumor antigens. To identify TCRs as cell therapy candidates, Zelluna...
BioCentury | Oct 26, 2018
Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

...She is a scientific co-founder of oncolytic vector company Oncorus Inc. (Cambridge, Mass.). Immunotherapy company Zelluna Immunotherapy A/S...
BioCentury | Aug 13, 2018
Company News

Management tracks: FDA, Allergan

...James Murphy as CFO. He was CFO at VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) Immunotherapy company Zelluna Immunotherapy A/S...
Items per page:
1 - 6 of 6
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...undisclosed company. The cancer and rare disease company has launched a search for his successor. Zelluna Immunotherapy A/S...
...is developing TCR-based autologous T and allogeneic NK cell therapies to treat solid tumors (see "Zelluna’s...
...Afa Science’s board and is an advising partner at Advantary, which outsources C-suite services. BioCentury Staff Xencor Institut Gustave-Roussy Zelluna Immunotherapy A/S E-Scape...
BioCentury | Nov 19, 2019
Company News

Nov. 19 Company Quick Takes: Medicines Co. gains on buyout rumor; plus Samsung's biosimilar under review and Zelluna-Glycostem

...commercialize the anti-VEGF antibody in the U.S. Zelluna, Glycostem to develop allogeneic TCR-NK cell therapies Zelluna Immunotherapy A/S...
...Therapeutics B.V.'s umbilical cord-derived NK cells to develop allogeneic TCR-expressing NK cells for solid tumors. Zelluna...
...Vascular endothelial growth factor BioCentury Staff Samsung Bioepis Co. Ltd. Biogen Inc. Merck & Co. Inc. Samsung BioLogics Co. Ltd. Zelluna Immunotherapy A/S The...
BioCentury | Mar 22, 2019
Product Development

Regulating regeneration in Europe

...differences between regulatory pathways in Europe, the U.S. and Japan, said Miguel Forte, CEO of Zelluna Immunotherapy A/S...
...on things like GMOs and how they are regulated is a delaying obstacle." Miguel Forte, Zelluna...
...Administration (FDA), Silver Spring, Md. Zelluna Immunotherapy A/S, Oslo, Norway Lauren Martz, Associate Editor Caladrius Biosciences Inc. Celixir plc ReNeuron Group plc Zelluna Immunotherapy A/S ATMP regenerative...
BioCentury | Jan 17, 2019
Emerging Company Profile

Zelluna’s solid TCR plans

...attack on solid tumors than other TCR-based cell therapies in development. CEO Miguel Forte said Zelluna’s...
...whereas some cancers but few normal cells express HLA class II. Forte said this means Zelluna’s...
...can target a wider range of tumor antigens. To identify TCRs as cell therapy candidates, Zelluna...
BioCentury | Oct 26, 2018
Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

...She is a scientific co-founder of oncolytic vector company Oncorus Inc. (Cambridge, Mass.). Immunotherapy company Zelluna Immunotherapy A/S...
BioCentury | Aug 13, 2018
Company News

Management tracks: FDA, Allergan

...James Murphy as CFO. He was CFO at VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) Immunotherapy company Zelluna Immunotherapy A/S...
Items per page:
1 - 6 of 6